Alpine Immune Sciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-23
- Employees
- 142
- Market Cap
- $4.4B
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)
- Conditions
- Autoimmune Cytopenias (warm autoimmune hemolytic anemia [wAIHA], cold agglutinin disease [CAD], immune thrombocytopenia [ITP])
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Alpine Immune Sciences Inc.
- Target Recruit Count
- 30
- Registration Number
- 2023-507067-19-00
- Locations
- 🇺🇸
Investigational Site (230), Los Angeles, California, United States
🇺🇸Investigational Site (401), Washington, District of Columbia, United States
🇺🇸Investigational Site (419), Cooper City, Florida, United States
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
- Conditions
- Lupus NephritisImmunoglobulin A NephropathyMembranous NephropathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Alpine Immune Sciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05732402
- Locations
- 🇺🇸
Investigational Site (523), Phoenix, Arizona, United States
🇺🇸Investigational Site (501), Phoenix, Arizona, United States
🇺🇸Investigational Site (524), Tucson, Arizona, United States
A Study of ALPN-303 in Adult Healthy Volunteers
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alpine Immune Sciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05034484
- Locations
- 🇦🇺
Investigative Site, Melbourne, Victoria, Australia
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
- Conditions
- Advanced Solid TumorLymphoma
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Alpine Immune Sciences, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04920383
- Locations
- 🇺🇸
Investigational Site (213), Atlanta, Georgia, United States
🇺🇸Investigational Site (212), Boston, Massachusetts, United States
🇺🇸Investigational Site (301), Grand Rapids, Michigan, United States
ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alpine Immune Sciences, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT04835441
- Locations
- 🇺🇸
Investigational Site (107), Anniston, Alabama, United States
🇺🇸Investigational Site (189), Phoenix, Arizona, United States
🇺🇸Investigational Site (155), Los Angeles, California, United States
- Prev
- 1
- 2
- Next